Because EGFR is highly expressed in 43–89% of NSCLC (Scagliotti et al, 2004), EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib have emerged as particularly promising target drugs for treating NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.